Ben Whitehouse, head of Rare Diseases, Sanofi UK and Ireland, stated: “At Sanofi, we’re committed to creating fulfilling futures for extraordinary people. No matter how rare their condition.

Sanofi’s $9.5 billion deal includes Ayvakit, elenestinib, and BLU-808. Get access to the leaderboards pointing to tomorrow’s biggest stock movers. The acquisition includes a rare immunology ...

Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease ...

Sanofi still retains a sizeable capacity for further acquisitions.” Ayvakit achieved net revenues of $479 million in 2024 and nearly $150 million in Q1 2025, representing year-on-year growth of ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved ...